US2005245612A1PendingUtilityA1

Pharmaceutical compositions for metabolic insufficiencies

61
Individually held — no corporate assignee on recordPriority: May 3, 2004Filed: May 3, 2004Published: Nov 3, 2005
Est. expiryMay 3, 2024(expired)· nominal 20-yr term from priority
Inventors:John P. Blass
A61K 31/05A23L 2/02A23L 2/52A23G 1/42A23G 1/32A61K 31/7004A61K 31/137A23G 1/36A61K 33/06A61K 35/02A23L 33/10A61K 36/87A61K 36/82
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed in certain embodiments is a pharmaceutical composition comprising a sugar; a Krebs cycle intermediate, precursor of a Krebs cycle intermediate, salt thereof, or combination thereof; and a component selected from the group consisting of an unsaturated lipid, phenylethylamine, a soluble calcium compound, or a combination thereof.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition comprising: 
 a sugar;    a Krebs cycle intermediate, precursor of a Krebs cycle intermediate, salt thereof, or combination thereof; and    a component selected from the group consisting of an unsaturated lipid, phenylethylamine, a soluble calcium compound, a combination thereof, or a combination thereof.    
   
   
       2 . The pharmaceutical composition of  claim 1 , wherein the component is an unsaturated fatty acid.  
   
   
       3 . The pharmaceutical composition of  claim 1 , wherein the component is phenylethylamine.  
   
   
       4 . The pharmaceutical composition of  claim 1 , wherein the component is a soluble calcium compound.  
   
   
       5 . The pharmaceutical composition of  claim 1 , wherein the component is a combination of an unsaturated fatty acid and phenylethylamine.  
   
   
       6 . The pharmaceutical composition of  claim 1 , wherein the component is a combination of an unsaturated fatty acid and a soluble calcium compound.  
   
   
       7 . The pharmaceutical composition of  claim 1 , wherein the component is a combination of a phenylethylamine and a soluble calcium compound.  
   
   
       8 . The pharmaceutical composition of  claim 1 , wherein the unsaturated lipid is selected from the group consisting of unsaturated monoglycerides, unsaturated diglycerides, unsaturated triglycerides, unsaturated fatty acids, unsaturated fatty alcohols, unsaturated phosphatides, unsaturated sterols, unsaturated fat-soluble vitamins, unsaturated terpenes, and mixtures thereof.  
   
   
       9 . The pharmaceutical composition of  claim 1 , wherein the unsaturated lipid is selected from the group consisting of high oleic sunflower oil, sunflower oil, rapeseed oil, soybean oil, peanut oil, canola oil, cottonseed oil, coconut oil, palm oil, palm kernel oil, corn oil, flax seed oil, olive oil, safflower oil, fish oil, and mixtures thereof.  
   
   
       10 . The pharmaceutical composition of  claim 1 , wherein the unsaturated lipid is selected from the group consisting of flax seed oil, fish oil, and mixtures thereof.  
   
   
       11 . The pharmaceutical composition of  claim 1 , wherein the phenylethylamine is phenylethyl-2-amine.  
   
   
       12 . The pharmaceutical composition of  claim 1 , wherein the soluble calcium compound is selected from the group consisting of calcium lactate, calcium sulfate, calcium citrate, calcium malate, calcium gluconate and combinations thereof.  
   
   
       13 . The pharmaceutical composition of  claim 1 , wherein the soluble calcium compound is calcium malate.  
   
   
       14 . The pharmaceutical composition of to  claim 1 , wherein the Krebs cycle intermediate is selected from a group consisting of citric acid, aconitic acid, isocitric acid, a-ketoglutaric, succinic acid, fumaric acid, malic acid, oxaloacetic acid, and combinations thereof.  
   
   
       15 . The pharmaceutical composition of  claim 1 , wherein the precursor is selected from a group consisting of 2-keto-4-hydroxypropanol, 2,4-dihydroxybutanol, 2-keto-4-hydroxybutanol, 2,4-dihydroxybutyric acid, 2-keto-4-hydroxybutyric acid, aspartate, mono-alkyl esters of oxaloacetate, di-alkyl esters of oxaloacetate, and mixtures thereof.  
   
   
       16 . The pharmaceutical composition of  claim 1 , wherein the sugar is selected from the group consisting of a monosaccharide, disaccharide, polysaccharide, and mixtures thereof.  
   
   
       17 . The pharmaceutical composition of  claim 16 , wherein the monosaccharide is selected from a group consisting of glucose, fructose, mannose, galactose, and mixtures thereof.  
   
   
       18 . The pharmaceutical composition of  claim 16 , wherein the disaccharide is selected from a group consisting of sucrose, maltose, lactose, and mixtures thereof.  
   
   
       19 . The pharmaceutical composition of  claim 16 , wherein the polysaccharide is a starch.  
   
   
       20 . The pharmaceutical composition of  claim 1 , further comprising a mitochondrial function enhancing compound.  
   
   
       21 . The pharmaceutical composition of  claim 20 , wherein the mitochondrial function enhancing compound is selected from the group consisting of a vitamin, a mineral, an antioxidant, a metabolism-enhancing compound, and mixtures thereof.  
   
   
       22 . The pharmaceutical composition of  claim 21 , wherein the metabolism-enhancing compound is selected from the group consisting of creatine, L-carnitine, L-carnitine derivatives, and mixtures thereof.  
   
   
       23 . The pharmaceutical composition of to  claim 21 , wherein the vitamin is selected from the group consisting of thiamin, riboflavin, niacin, pyridoxine derivatives, pantothenic acid, and mixtures thereof.  
   
   
       24 . The pharmaceutical composition of  claim 21 , wherein the mineral is selected from the group consisting of calcium, magnesium, sodium, potassium, zinc, and mixtures thereof.  
   
   
       25 . The pharmaceutical composition of  claim 21 , wherein the antioxidant is selected from the group consisting of ascorbic acid, alpha-tocopherol, resveritrol, quercetin, and mixtures thereof.  
   
   
       26 . The pharmaceutical composition of  claim 1 , further comprising at least one pharmaceutically acceptable excipient.  
   
   
       27 . The pharmaceutical composition of  claim 1 , in the form of an oral solid dosage form, a parenteral product, an intramucosal product or a suppository.  
   
   
       28 . The pharmaceutical composition of  claim 1 , in the form of an edible solid or liquid.  
   
   
       29 . The pharmaceutical composition of  claim 1 , wherein the edible solid is in the form of a confectionary product.  
   
   
       30 . The pharmaceutical composition of  claim 1 , wherein the edible liquid comprises a fruit juice.  
   
   
       31 . A method of treating a disease associated with impaired mitochondrial function comprising administering a pharmaceutical composition of any of claims  1 - 30  to a patient in need thereof.  
   
   
       32 . The method of  claim 31 , wherein the disease is a nervous system disorder, a cardiovascular disorder or a musculoskeletal disorder.  
   
   
       33 . The method of  claim 32 , wherein the nervous system disorder is Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, spinocerebellar ataxia, or a psychosis.  
   
   
       34 . The method of  claim 32 , wherein the cardiovascular disorder is selected from the group consisting of atherosclerotic cardiovascular disease, cardiomyopathies, cardiac valvular disorders, and disorders causing cardiac failure.  
   
   
       35 . The method according to  claim 31 , wherein said administering is oral, rectal, parenteral, or by application to mucous membranes.  
   
   
       36 . A method of improving cerebral function comprising administering a pharmaceutical composition of  claim 1  to a patient in need thereof.  
   
   
       37 . The method of  claim 30 , wherein the pharmaceutical composition is in the form of an edible solid or liquid.  
   
   
       38 . The method of  claim 30 , wherein the edible solid is in the form of a confectionary product.  
   
   
       39 . The method of  claim 30 , wherein the edible liquid comprises a fruit juice.  
   
   
       40 . The method of  claim 30 , wherein the pharmaceutical formulation is in the form of chewable or edible bars, confectionary products, cookies, baked or simulated baked goods, biscuits, lozenges, juice drinks or chewing gum.  
   
   
       41 . A chocolate food product comprising cocoa, edible filler and added 2-phenylethylamine, wherein the ratio of the amount of 2-phenylethylamine in the product as compared to the 2-phenylethylamine provided by the cocoa and edible filler is at least 2:1.

Join the waitlist — get patent alerts

Track US2005245612A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.